GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vaso Corporation (OTCPK:VASO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Vaso (VASO) Cash, Cash Equivalents, Marketable Securities : $23.77 Mil (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vaso Cash, Cash Equivalents, Marketable Securities?

Vaso's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($26.89 Mil) to Dec. 2023 ($25.32 Mil) but then stayed the same from Dec. 2023 ($25.32 Mil) to Mar. 2024 ($23.77 Mil).

Vaso's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($6.65 Mil) to Dec. 2022 ($20.33 Mil) and increased from Dec. 2022 ($20.33 Mil) to Dec. 2023 ($25.32 Mil).


Vaso Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Vaso's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaso Cash, Cash Equivalents, Marketable Securities Chart

Vaso Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.12 7.59 6.65 20.33 25.32

Vaso Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.25 26.07 26.89 25.32 23.77

Vaso Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Vaso  (OTCPK:VASO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Vaso Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Vaso's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaso (VASO) Business Description

Industry
Traded in Other Exchanges
N/A
Address
137 Commercial Street, Unit 200, Plainview, NY, USA, 11803
Vaso Corporation is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.
Executives
Leon Dembo director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Janey Moen director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Jun Ma director C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Edgar Rios director 1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102
Michael Beecher officer: Chief Financial Officer C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716
Joshua Markowitz director 3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648
Jonathan P Newton officer: Vice Pres Finance & Controller 152 RICHMOND AVENUE, AMITYVILLE NY 11701
Peter C Castle director C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634
David H Lieberman director 3061 INDUSTRY DR, LANCASTER PA 17603
Behnam Movaseghi director C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101
Nelson Randall Hill officer: Senior Vice President 3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159
William Edward Dempsey director 52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4
David Tarachand Singh officer: Chief Financial Officer C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Joseph Giacalone director
Derek Enlander director 88C UNION AVENUE, CENTER MORICHES NY 11934